General Proximity
The next generation of induced-proximity medicines.
About General Proximity
General Proximity is a seed-stage biotechnology platform company founded in 2019 that pioneers the next generation of induced-proximity medicines for undruggable targets. The company's proprietary OmniTAC platform enables precise and selective modification of disease-driving proteins, targeting oncology, cardiometabolic disease, neurodegeneration, and longevity indications. It serves pharmaceutical and biotechnology research organizations seeking non-occupancy-driven therapeutic strategies for previously intractable molecular targets.
Company details
Funding
Total raised
$16M
Last stage
Seed
Investors
Founders
Armand Cognetta
Armand completed his PhD in Chemical Biology at the Scripps Research Institute under the supervision of Dr. Benjamin F. Cravatt. There he co-authored 19 scientific publications in prestigious journals such as Cell, Nature, and Science, as well as multiple patents, including a portion of the foundational IP for Abide Therapeutics (acq. Lundbeck) and Vividion Therapeutics (acq. Bayer). Prior to founding GP he was an early employee at the Flagship Pioneering start-up Inzen Tx (now Sonata).
Armand B. Cognetta III
PhD in Chemical Biology from the Scripps Research Institute under Dr. Benjamin Cravatt. Co-authored 19 scientific publications in Cell, Nature, and Science. Early employee at Flagship Pioneering's Inzen Therapeutics. Went through Y Combinator as a solo founder to launch General Proximity.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.